Phase II study of neoadjuvant Letrozole combined with low dose metronomic Cyclophosphamide for postmenopausal women with Endocrine-responsive Breast Cancer (JBCRG-07) - JBCRG-07

Japan Breast Cancer Research Group (JBCRG)0 个研究点目标入组 41 人开始时间: 2008年8月22日最近更新: 2023年11月20日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方
入组人数: 41

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

Results: The CRR was 67.5% '52.0-80.0%). No patients achieved pCR. Seven patients (17.5%) showed grade 2 pathological responses and 28 (70%) showed grade 1 responses. Conclusion: Metronomic chemo-endocrine therapy with letrozole plus cyclophosphamide showed a good response and was tolerated in Japanese postmenopausal patients with ER-positive breast cancer.

研究设计

研究类型: Interventional

入排标准

年龄范围: 60years-old 至 ot applicable（—）
性别: Female

入选标准

未提供

排除标准

•1. Prior chemotherapy or endocrine therapy 2. Under treatment by medicines with the possibility to affect the state of the sex hormone (hormone replacement therapy or raloxifene, etc) 3. Active double cancer 4. Inflammatory breast cancer 5. Bilateral breast cancer 6. History of drug-hypersensitivity 7. Under treatment of investigational new drug for other disease except breast cancer 8. Mental disease 9. Patient judged inappropriate for this study by the physicians

研究者

发起方

Japan Breast Cancer Research Group (JBCRG)

相似试验

已完成

不适用

A Phase III Study to Evaluate Letrozole as Adjuvant Endocrina Therapy for Postmenopausal Women with Receptor (ER and/or PgR) Positive Tumors-C509 Breast, unspecifiedBreast, unspecifiedC509

PER-051-00OVARTIS BIOSCIENSES PERU S.A.,

暂停

2 期

Study of neoadjuvant Letrozole combined with standerd chemotherapy for postmenopausal women with Endocrine-responsive Breast Cancer(subject of stage2,3A)Postmenopausal, hormone-receptor positive and resectable primary breast cancer

JPRN-UMIN000002447iigata Cancer Center Hospital80

已完成

3 期

Adjuvant Therapy for Postmenopausal Patients with Operable Breast Cancer who have Estrogen Receptor or Progesterone Receptor Positive Tumors.Tamoxifen vs. Letrozole vs. Tamoxifen followed by Letrozole vs. Letrozole followed by TamoxifeBreast Cancer

ACTRN12607000012471ovartis Pharma AG, Basel6,193

已完成

2 期

Evaluation of efficacy of letrozole as a neoadjuvant endocrine therapy in postmenopausal patients with hormone receptor-positive breast cancerBreast cancer

JPRN-UMIN000003101Tohoku University Graduate School of Medicine30

Unknown

2 期

Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal WomenER Positive, HER2 Negative Breast Cancer

NCT01709370Organisation for Oncology and Translational Research45